Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.08 USD | +0.49% |
|
+3.03% | -13.19% |
05-21 | Oppenheimer Adjusts Savara Price Target to $11 From $9.50, Maintains Outperform Rating | MT |
05-09 | Savara Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.19% | 564M | |
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- SVRA Stock
- News Savara Inc.
- Savara : Doses First Patient in Late-Stage Trial of Molgramostim in Lung Disease